company background image
ATHE logo

Alterity Therapeutics NasdaqCM:ATHE Stock Report

Last Price

US$1.07

Market Cap

US$10.4m

7D

-3.2%

1Y

-42.2%

Updated

24 Nov, 2024

Data

Company Financials +

Alterity Therapeutics Limited

NasdaqCM:ATHE Stock Report

Market Cap: US$10.4m

ATHE Stock Overview

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. More details

ATHE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Alterity Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alterity Therapeutics
Historical stock prices
Current Share PriceAU$1.07
52 Week HighAU$5.41
52 Week LowAU$1.00
Beta0.68
11 Month Change-7.76%
3 Month Change-21.32%
1 Year Change-42.16%
33 Year Change-89.71%
5 Year Change-88.37%
Change since IPO-99.84%

Recent News & Updates

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

Shareholder Returns

ATHEUS BiotechsUS Market
7D-3.2%2.5%2.2%
1Y-42.2%16.1%31.6%

Return vs Industry: ATHE underperformed the US Biotechs industry which returned 16.2% over the past year.

Return vs Market: ATHE underperformed the US Market which returned 31.7% over the past year.

Price Volatility

Is ATHE's price volatile compared to industry and market?
ATHE volatility
ATHE Average Weekly Movement8.9%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: ATHE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ATHE's weekly volatility has decreased from 25% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199710David Stamleralteritytherapeutics.com

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.

Alterity Therapeutics Limited Fundamentals Summary

How do Alterity Therapeutics's earnings and revenue compare to its market cap?
ATHE fundamental statistics
Market capUS$10.37m
Earnings (TTM)-US$12.43m
Revenue (TTM)US$2.61m

4.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATHE income statement (TTM)
RevenueAU$4.02m
Cost of RevenueAU$214.30k
Gross ProfitAU$3.80m
Other ExpensesAU$22.93m
Earnings-AU$19.12m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0036
Gross Margin94.67%
Net Profit Margin-475.79%
Debt/Equity Ratio0%

How did ATHE perform over the long term?

See historical performance and comparison